Table 2 Sex-stratified study parameters and comparison of acute COVID-19 infection (acute) and FU1–FU2.
Gender | Acute | FU1 | FU2 | |||
|---|---|---|---|---|---|---|
Median (IQR) | p-value* | meDian (IQR) | p-value ** | Median (IQR) | ||
Neopterin [nmol/L] | Male | 26.3 (17.7–44.4) | < 0.001 | 8.9 (8.0–13.0) | n.s | 7.8 (7.1–9.3) |
Female | 41.1 (18.3–45.7) | 0.038 | 12.5 (9.1–18.9) | 0.069 | 6.5 (5.8–8.9) | |
Kyn [µmol/L] | Male | 3.1 (2.3–3.8) | 0.049 | 2.3 (1.8–3.0) | n.s | 2.5 (2.2–2.7) |
Female | 3.5 (3.1–4.0) | 0.051 | 2.4 (2.2–2.5) | n.s | 2.3 (2.0–3.1) | |
Trp [µmol/L] | Male | 45.4 (40.8–52.4) | 0.040 | 52.8 (48.2–59.8) | 0.061 | 62.0 (58.8–69.3) |
Female | 41.2 (35.7–51.5) | n.s | 54.4 (40.8–54.9) | 0.012 | 65.9 (60.9–70.6) | |
Phe [µmol/L] | Male | 125.3 (114.2–134.8) | < 0.001 | 69.9 (64.4–87.2) | n.s | 84.1 (73.4–92.5) |
Female | 129.9 (113.7–157.1) | 0.008 | 60.9 (56.4–69.3) | 0.025 | 73.3 (68.7–95.1) | |
Tyr [µmol/L] | Male | 66.3 (58.9–72.5) | n.s | 58.3 (54.0–67.2) | 0.020 | 81.0 (66.8–92.2) |
Female | 62.6 (57.9–73.4) | n.s | 59.8 (57.3–72.9) | 0.012 | 78.3 (68.3–91.0) | |
Kyn/Trp [µmol/mmol] | Male | 63.8 (51.2–83.4) | 0.006 | 39.3 (33.7–55.5) | n.s | 37.6 (36.3–44.1) |
Female | 82.6 (61.4–96.9) | 0.028 | 45.5 (41.0–56.8) | 0.025 | 36.0 (32.3–44.5) | |
Phe/Tyr [µmol/µmol] | Male | 1.9 (1.7–2.1) | < 0.001 | 1.2 (1.0–1.4) | 0.088 | 1.0 (0.9–1.1) |
Female | 2.0 (1.6–2.3) | 0.008 | 1.0 (1.0–1.1) | n.s | 1.0 (0.9–1.0) | |
Nitrite [µmol/L] | Male | 23.3 (13.8–45.4) | n.s | 29.6 (11.8–55.6) | 0.005 | 8.8 (8.4–17.2) |
Female | 22.4 (13.3–33.2) | n.s | 16.5 (10.7–52.4) | 0.036 | 7.7 (5.7–14.9) | |
Folate [µg/L] | Male | 10.3 (5.3–11.9) | 0.048 | 5.6 (4.5–8.3) | 0.028 | 7.7 (6.1–10.8) |
Female | 15.4 (13.1–17.6) | n.s | 7.5 (4.9–16.6) | n.s | 16.9 (10.3–20.0) | |
Vitamin B12 [pmol/mL] | Male | 376 (268–493) | 0.026 | 234 (188–327) | n.s | 282 (217–395) |
Female | 604 (374–826) | n.s | 352 (311–535) | n.s | 383 (302–581) | |
WBC [G/L] | Male | 6.0 (3.6–7.4) | n.s | 6.3 (5.3–7.4) | n.s | 6.9 (5.9–7.7) |
Female | 6.5 (6.1–10.4) | n.s | 7.1 (6.5–8.4) | 0.018 | 5.7 (5.3–7.2) | |
Hemoglobin [g/L] | Male | 124 (119–137) | n.s | 134 (123–145) | < 0.001 | 156 (139–161) |
Female | 116 (112–136) | n.s | 124 (122–134) | 0.063 | 133 (128–137) | |
MCV [fL] | Male | 89.0 (86.4–91.3) | < 0.001 | 90.8 (89.4–94.6) | 0.022 | 89.6 (88.1–92.1) |
Female | 91.2 (87.5–93.3) | 0.017 | 93.5 (91.7–93.9) | 0.018 | 88.5 (86.4–90.0) | |
MCH [pg] | Male | 30.9 (30.2–31.5) | n.s | 30.5 (29.8–31.6) | 0.018 | 31.1 (30.8–31.6) |
Female | 30.8 (29.3–31.9) | n.s | 30.9 (29.9–32.0) | 0.028 | 29.9 (28.1–31.4) | |
Lymphocytes [% of WBC] | Male | 15.8 (10.0–23.9) | 0.001 | 25.2 (21.0–29.8) | 0.027 | 31.6 (26.7–35.2) |
Female | 10.7 (9.4–34.3) | n.s | 29.4 (18.8–33.3) | n.s | 31.6 (25.4–35.0) | |
CRP [mg/dL] | Male | 9.41 (3.5–17.06) | < 0.001 | 0.20 (0.06–0.56) | n.s | 0.15 (0.06–0.30) |
Female | 3.42 (1.94–21.53) | 0.018 | 0.13 (0.08–0.63) | n.s | 0.25 (0.09–0.82) | |
IL-6 [ng/L] | Male | 85.8 (32.6–205.4) | < 0.001 | 3.1 (1.5–7.3) | n.s | 1.5 (1.5–4.3) |
Female | 28.5 (12.3–171.8) | 0.012 | 3.2 (1.5–6.5) | 0.068 | 1.5 (1.5–2.6) | |
LDH [U/L] | Male | 352 (252–400) | < 0.001 | 206 (193–224) | n.s | 195 (171–220) |
Female | 314 (238–382) | 0.093 | 221 (213–251) | n.s | 201 (189–238) | |
Total serum iron [µmol/L] | Male | 4.2 (3.1–5.7) | < 0.001 | 15.4 (8.7–20.1) | n.s | 15.2 (12.8–21.0) |
Female | 4.3 (2.4–15.8) | 0.012 | 16.3 (11.4–17.7) | n.s | 14.0 (8.0–18.2) | |
Ferritin [µg/L] | Male | 1420 (572–2053) | < 0.001 | 280 (137–469) | 0.004 | 160 (112–272) |
Female | 632 (469–973) | 0.018 | 193 (91–305) | 0.063 | 91 (50–170) | |
Transferrin saturation [%] | Male | 13.0 (10.0–17.0) | 0.004 | 26.0 (13.0–37.0) | n.s | 24.0 (20.0–32.0) |
Female | 10.0 (9.0–33.0) | 0.063 | 25.5 (19.0–31.0) | n.s | 22.0 (12.0–33.5) | |
